更新于：2024-12-17
Phytonadione
维生素K1
更新于：2024-12-17
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1955-09-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C31H46O2 |
InChIKeyMBWXNTAXLNYFJB-NKFFZRIASA-N |
CAS号84-80-0 |
关联
90
项与 维生素K1 相关的临床试验The Role of Vitamin K on Knee Osteoarthritis Outcomes
评估受试制剂维生素K1片（规格：5 mg）与参比制剂维生素K1片（规格：5 mg）在健康成年参与者餐后状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性试验
评估受试制剂维生素K1片（规格：5 mg）与参比制剂维生素K1片（规格：5 mg）在健康成年参与者空腹状态下的单中心、开放、随机、单剂量、四周期、两序列、完全重复交叉生物等效性试验
100 项与 维生素K1 相关的临床结果
登录后查看更多信息
100 项与 维生素K1 相关的转化医学
登录后查看更多信息
100 项与 维生素K1 相关的专利（医药）
登录后查看更多信息
15,106
项与 维生素K1 相关的文献（医药）2025-02-01FOOD CHEMISTRY
Vitamin K - content in food and dietary intake among the Danes
Article
作者: Jakobsen, Jette ; Christensen, Tue ; Langwagen, Marija ; Poulsen, Anders ; Jensen, Marie Bagge
Insufficient information on the content of vitamin K2 in our foods hinder estimation of the dietary intake. We aimed to establish content of eight vitamin K vitamers, vitamin K1 (phylloquinone; PK) and vitamin K2 (menaquinones; MK-4 to MK-10) in 88 composite food samples representing dairy, eggs, meat, fish, cereals, and plant-based alternatives to dairy. Combined with PK data for other foods, the dietary intake among Danes was estimated. The unit'PKeq' is used to compensate for the difference in molecular weight for MK-4 at 445 g/mol up to MK-10 at 853 g/mol. The highest content was found in chicken thigh with skin at 53 μg PKeq/100 g followed by 49 μg PKeq/100 g in Danablue (blue cheese). The daily intake of vitamin K is 139 μg to 160 μg PKeq for adults. The highest percentage comes from PK (64 %), 27 % from MK-4, 4.6 % from MK-9, and 2.4 % from MK-8.
2025-02-01EUROPEAN JOURNAL OF NUTRITION
Investigating the associations between uncarboxylated matrix gla protein as a proxy for vitamin K status and cardiovascular disease risk factors in a general adult population
Article
作者: Dantoft, Thomas Meinertz ; Kofoed, Klaus Fuglsang ; Lauridsen, Julie Aaberg ; Linneberg, Allan ; Leth-Møller, Katja Biering ; Kårhus, Line Lund ; Møllehave, Line Tang
Abstract:
Purpose:
Vitamin K is an activator of vitamin K dependent proteins, one of which is the potent inhibitor of vascular calcification, matrix Gla protein (MGP). The purpose of this study is to investigate the association between an inverse proxy of functional vitamin K status, plasma dephospho-uncarboxylated MGP (dp-ucMGP), and cardiovascular disease risk factors (CVDRFs).
Methods:
In a cross-sectional population-based health examination study of 4,092 individuals aged 24–77 years, the vitamin K status was assessed using plasma dp-ucMGP. All participants were linked to Danish National Prescription Register to obtain information on the use of vitamin K antagonists. The associations between log2 transformed dp-ucMGP values and CVDRFs were determined using regression models adjusted for sex, age, lifestyle factors, kidney function and waist circumference.
Results:
Higher dp-ucMGP levels were associated with increased risk of central obesity (Odds Ratio (OR) 4.76, 95% Confidence Intervals (CI) 3.57–6.34), diabetes (OR 1.96, 95% CI 1.11–3.45), hyperlipidaemia (OR 1.43, 95% CI 1.01–2.03), and impaired kidney function (OR 9.83, 95% CI 5.49–17.59) per doubling in dp-ucMGP. Dp-ucMGP was not independently associated with hypertension or arterial stiffness.
Conclusion:
Higher dp-ucMGP levels were associated with central obesity, diabetes, hyperlipidaemia, and impaired kidney function. Prospective studies and intervention studies examining the effects of improving vitamin K status are needed to clarify the potential role of vitamin K in relation to these CVDRFs.
2025-02-01AMERICAN HEART JOURNAL
Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS
Article
作者: Vora, Amit N ; Goodman, Shaun G. ; Alexander, John H ; Windecker, Stephan ; Wojdyla, Daniel M ; Vora, Amit N. ; Aronson, Ronald ; Fanaroff, Alexander C ; Alexander, John H. ; Granger, Christopher B ; Lopes, Renato D ; Goodman, Shaun G ; Granger, Christopher B. ; Fanaroff, Alexander C. ; Mehran, Roxana ; Wojdyla, Daniel M.
BACKGROUND:
Clinical trials of antithrombotic agents typically use separate time-to-event analyses for bleeding and ischemic events, but this framework has limitations. Days alive and out of hospital (DAOH) is an alternative that may provide additional insight. We assessed the utility of DAOH as a clinical trial endpoint among patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention METHODS: AUGUSTUS, a randomized clinical trial, compared apixaban with warfarin and aspirin with placebo in 4614 patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention. We used Poisson regression with a robust variance estimate to compare DAOH by treatment group.
RESULTS:
Mean (SD) DAOH was 168 (31); median (IQR) was 177 (169-180); 75% of patients neither died nor were hospitalized. Mean (SD) DAOH was 169 (28) with apixaban + placebo, 168 (29) with apixaban + aspirin, 168 (33) with warfarin + placebo, and 167 (33) with warfarin + aspirin. There were no significant differences in the rate ratio for DAOH for apixaban vs. warfarin (RR 1.00, 95% CI 0.99-1.01) or aspirin vs. placebo (RR 1.00, 95% CI 1.00-1.01). Compared with warfarin, apixaban increased the proportion of patients who neither died nor were hospitalized during follow-up (76.8 vs. 73.3%; OR 0.83, 95% CI 0.73-0.95).
CONCLUSION:
In this analysis of AUGUSTUS, there was no difference in DAOH by treatment arm. These findings contrast with time-to-event analyses, which showed lower rates of major bleeding and hospitalization with apixaban and placebo. DAOH may not be very a useful measure of effects of antithrombotic therapies in this population.
TRIAL REGISTRATION:
clinicaltrials.gov; NCT02415400; https://clinicaltrials.gov/study/NCT02415400.
100 项与 维生素K1 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 维生素K缺乏症 | 日本 | 1962-03-31 | |
| 低凝血酶原血症 | 美国 | 1955-09-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 凝血障碍 | 申请上市 | 加拿大 | 2021-06-17 | |
| 维生素K缺乏性出血 | 临床1期 | 中国 | 2023-07-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | - | 2023-08-28 | |||
N/A | 肝细胞癌 protein-induced by vitamin K absence (PIVKA-II) | serum a-fetoprotein (AFP) | 168 | 夢顧積積願憲獵夢獵築(獵願獵醖鏇鬱淵製製夢) = 繭憲顧選夢廠蓋鹹窪繭 憲壓鹹憲餘製繭夢壓製 (艱簾淵齋鹽範艱鏇醖憲 ) 更多 | - | 2022-06-25 | ||
(Control group) | 夢顧積積願憲獵夢獵築(獵願獵醖鏇鬱淵製製夢) = 簾構顧網齋淵鹹壓鏇襯 憲壓鹹憲餘製繭夢壓製 (艱簾淵齋鹽範艱鏇醖憲 ) 更多 | ||||||
N/A | - | Vitamin K1 supplement | 鹽鹹鑰窪簾醖蓋憲觸鹹(齋醖築獵觸鏇積鹽構廠) = 鹽淵簾選網範淵鬱鑰製 顧鹽夢鏇窪鹹構製醖夢 (顧遞簾遞夢簾遞顧憲壓 ) 更多 | - | 2015-08-01 | ||
(Placebo) | 鹽鹹鑰窪簾醖蓋憲觸鹹(齋醖築獵觸鏇積鹽構廠) = 壓鏇繭觸窪壓鬱糧觸蓋 顧鹽夢鏇窪鹹構製醖夢 (顧遞簾遞夢簾遞顧憲壓 ) 更多 | ||||||
N/A | 16 | vitamin K+arnica | 廠遞憲餘鏇窪蓋獵淵網(觸鏇醖膚鏇範餘淵膚顧) = 顧鏇醖窪簾衊範顧積構 壓簾糧壓鑰蓋願願願鏇 (壓構膚積積糧艱衊構築, 鬱範憲願膚襯齋艱網鹹 ~ 淵夢顧願壓齋糧淵鑰鹹) 更多 | - | 2012-12-04 | ||
临床1期 | 96 | (Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)) | 選膚遞憲遞蓋鑰餘遞網(衊襯顧製廠淵蓋憲網壓) = 獵淵鹹鹽願襯廠鑰築築 衊遞壓廠醖觸獵遞構憲 (艱製餘鑰遞築膚遞願鑰, 艱廠鑰壓鹽觸醖鹽願範 ~ 範積願願糧鏇繭醖鑰簾) 更多 | - | 2012-04-26 | ||
(Warfarin Followed by Placebo) | 選膚遞憲遞蓋鑰餘遞網(衊襯顧製廠淵蓋憲網壓) = 顧鹹積廠繭憲製獵壓顧 衊遞壓廠醖觸獵遞構憲 (艱製餘鑰遞築膚遞願鑰, 製醖構願襯獵範鹽製繭 ~ 糧願繭糧蓋構繭範壓鏇) 更多 | ||||||
N/A | 120 | 繭鏇鹹築齋簾蓋餘積憲(鹹襯壓醖繭獵製簾獵糧) = 窪鬱襯網構憲簾積範齋 選遞積築鏇觸製製顧齋 (鬱窪襯襯醖膚壓襯廠製 ) | - | 2010-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用